Amgen Stock Trades Above Consensus Targets Amid Double-Digit Revenue Growth

Amgen Inc.'s stock is trading at around $441.86 in late August 2026, marking a price significantly above analysts' average target of $380.43. According to recent data, the company's market capitalization stands at $239.07 billion. This represents a premium valuation for Amgen, with its price-to-earnings ratio sitting at 27.57.

The stock has been trading steadily within a tight range, with an intraday low of $441.26 and a high of $447.01 on August 26, 2026. This indicates that market participants are willing to pay a premium relative to average modeled valuation, potentially reflecting confidence in the company's double-digit revenue growth.

Amgen has set its full-year 2026 guidance for earnings per share (EPS) in a range of $22.30 to $23.50 on a reported basis. Analysts project full-year 2026 EPS of 22.92, placing the consensus estimate slightly above the midpoint of management's guidance range.

The company has delivered revenue growth of 12 percent in its latest reported period, driven by double-digit expansion across 16 different products. However, the increase in non-GAAP EPS was limited to 1 percent given higher operating expenses and tax costs. This discrepancy between revenue growth and EPS growth suggests that incremental sales are being partially offset by investment in research and development, commercialization, or administrative functions as well as a less favorable tax environment.